deltatrials
Unknown PHASE4 INTERVENTIONAL 2-arm NCT00751374

Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis

Prospective, Randomized, Open-Label Study of Topical Antibiotic Prophylaxis at the Catheter Exit Site: Continuous Daily Gentamicin Cream Versus Cyclical Gentamicin Cream and Mupirocin 2% Cream Alternating at Monthly Basis.

Sponsor: Kwong Wah Hospital

Conditions Rate of Atypical Mycobacterial Infection Rate of Exit Site Infection Rate of Peritoneal Dialysis
Interventions gentamicin gentamicin cream alternating with mupirocin cream
Updated 5 times since 2017 Last updated: Sep 10, 2008 Started: Sep 30, 2008 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Rate of Atypical Mycobacterial Infection and Rate of Exit Site Infection and is currently ongoing. Kwong Wah Hospital leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Study Description(click to expand)

Topical antibiotics therapy is a well-recognized prophylactic therapy towards the catheter exit site infection in peritoneal dialysis patient. Previous data has shown the superiority of gentamicin cream over the mupirocin cream in this aspect. However, the efficacy of the combination therapy using gentamicin cream alternating with mupirocin cream has not been tested. There is a potention benefit of reducing drug resistant strain in the combination group theoretically.

Topical antibiotics therapy is a well-recognized prophylactic therapy towards the catheter exit site infection in peritoneal dialysis patient. Previous data has shown the superiority of gentamicin cream over the mupirocin cream in this aspect. However, the efficacy of the combination therapy using gentamicin cream alternating with mupirocin cream has not been tested. There is a potention benefit of reducing drug resistant strain in the combination group theoretically.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 19 months · monthly snapshotUnknown~Jan 2026 – present · 3 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Jan 2026 — Present [monthly]

    Unknown PHASE4

  2. Sep 2024 — Present [monthly]

    Unknown PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  5. Jan 2017 — Jan 2021 [monthly]

    Unknown Status PHASE4

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kwong Wah Hospital
  • The Hong Kong Society of Nephrology
Data source: Kwong Wah Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations